CompletedPhase 2

The POWERED Study: Prophylaxis With Metformin to Prevent PTDM

United Kingdom60 participantsStarted 2019-01-25

Plain-language summary

PrOphylaxis With mEtformin to pREvent PTDM: a single site, placebo controlled, double blind randomised clinical trial evaluating the effectiveness of metformin to prevent post-transplant diabetes in a cohort of patients undergoing renal transplantation.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients (male or female) undergoing renal transplantation under the care of the Barts Health NHS Trust Renal Department
✓. Aged 18-75 inclusively
✓. Willing to comply with study schedule

Exclusion criteria

✕. History of Type 1 or type 2 diabetes
✕. Clinically significant history of abnormal physical and/or mental health as judged by the investigator other than conditions related to chronic kidney disease
✕. Participation in an investigational drug trial in the 3 months prior to administration of the initial dose of study drug
✕. Subject with a known hypersensitivity or contraindication to Tacrolimus
✕. Subject with a known hypersensitivity or contraindication to Metformin
✕. Pregnant or breast feeding

What they're measuring

Diagnosis of post-transplant diabetes

Timeframe: 12 months post-renal transplant

Trial details

NCT IDNCT05240274

SponsorBarts & The London NHS Trust

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-05-30

View on ClinicalTrials.gov More Post-transplant Diabetes Mellitus trials